RxDoctor Payments Data

Charles Shipman, MD

General Practice · Jasper, ALNPI 1508898198

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 367 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,030 and has fallen 50.3% since, to $512 in 2025. Among general practice clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,899in general payments, 2019–2025

Across 367 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$962
  • Johnson & Johnson$722
  • Amgen$317
  • Paratek Pharmaceuticals, Inc.$288
  • Takeda Pharmaceuticals U.S.A., Inc.$267
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,78798%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,899 in reported general payments places this provider in the 95th percentile of 1,114 general practice providers in Alabama.

See all general practice providers in Alabama

Medicare billing

Part B allowed, 2024
$126,939
Medicare patients
131
Services billed
5,947

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol209$147,089
OzempicSemaglutide128$119,078
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$70,123
LinzessLinaclotide104$64,741
MounjaroTirzepatide56$59,367
Nurtec OdtRimegepant Sulfate24$58,602
EliquisApixaban43$46,576
JardianceEmpagliflozin56$45,032
JanuviaSitagliptin Phosphate56$44,787
XareltoRivaroxaban53$39,876
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$38,868
TrintellixVortioxetine Hydrobromide42$34,289
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr70$32,066
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,080$26,568
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,152$25,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,361$185,956261 claims
Novo NordiskOzempic, Rybelsus$152$130,917141 claims
PfizerNurtec Odt, Eliquis, Premarin$217$111,79283 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy$962$106,492187 claims
Lilly USA, LLCMounjaro, Trulicity$36$73,79671 claims
AbbVieLinzess$142$64,741104 claims
Boehringer IngelheimJardiance$113$45,03256 claims
MerckJanuvia$228$44,78756 claims
Johnson & JohnsonXarelto$722$39,87653 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$267$34,28942 claims
Astellas Pharma US IncMyrbetriq$141$23,91246 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,114 general practice providers in Alabama.

Other general practice in Jasper

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →